Masimo (MASI) Aandeel Koers
Masimo Koers
In de afgelopen 19 jaar liet Masimo de omzet jaarlijks met 10,6% groeien tot 1,53 Miljard USD. De winst per aandeel is de afgelopen 17 jaar met 11,0% per jaar gedaald. Bij Masimo is de nettowinstmarge met -9,9% ten opzichte van 18,5% enkele jaren geleden gedaald. Op de huidige koers komt het dividendrendement uit op ongeveer 0,56%. De uitkeringsratio ligt rond 93% van de winst. Het consensus-koersdoel voor Masimo op 12 maanden bedraagt 183,60 USD, circa 2,0% boven de huidige koers. Van de 16 analisten geven 12 het aandeel een koopadvies — per saldo een Kopen-consensus.
Masimo aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
Masimo bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over Masimo
The business model of Masimo Corp focuses on providing innovative noninvasive monitoring technologies. Masimo develops and manufactures a wide range of medical devices and sensors to improve patient outcomes and reduce healthcare costs. The company's flagship product, Masimo SET®, revolutionized pulse oximetry by offering accurate measurements even in challenging conditions. With a dedication to patient safety and care, Masimo Corp combines advanced signal processing and sensor technology to deliver reliable monitoring solutions to healthcare professionals. Through their product portfolio, Masimo Corp aims to enhance patient care and promote efficiency in the healthcare industry.
Masimo Corp is primarily active in the medical device industry.
The main competitors of Masimo Corp in the market include companies such as Philips Healthcare, Nihon Kohden Corporation, and Smiths Medical.
Masimo Corp is a leading global medical technology company specializing in noninvasive patient monitoring. Founded in 1989 by Joe Kiani, the company has a rich history of innovation and advancements in the healthcare industry. Masimo Corp's core business revolves around developing and manufacturing advanced monitoring technologies, including pulse oximeters and signal extraction technology. With its commitment to improving patient outcomes and reducing healthcare costs, Masimo Corp has revolutionized the way healthcare professionals monitor patients' vital signs. Today, it is recognized as a trusted name in the medical device industry, providing innovative solutions that enhance patient care and safety worldwide.
Masimo Corp has achieved several significant milestones. Some noteworthy accomplishments include the development of breakthrough technologies in noninvasive patient monitoring, such as SET® pulse oximetry. The company has also received numerous awards and recognition for its innovative products and contributions to the healthcare industry. Masimo Corp has successfully expanded its global presence and formed strategic partnerships with leading healthcare organizations worldwide. Additionally, the company has consistently shown strong financial performance and steady revenue growth over the years. Overall, Masimo Corp continues to make strides in advancing patient care through its cutting-edge technologies and industry leadership.
Masimo Corp is primarily present in various countries and regions across the globe. Some notable markets where the company operates include the United States, European countries like Germany, France, and the United Kingdom, as well as Asian countries including Japan and China. Masimo Corp's global presence enables it to provide its innovative healthcare solutions, including noninvasive patient monitoring technologies, to healthcare facilities and professionals worldwide.
Masimo Corp represents a strong commitment to improving patient outcomes and reducing healthcare costs through innovative medical technologies. The company values include a dedication to patient safety, quality, and continuous improvement. Masimo's corporate philosophy revolves around providing noninvasive monitoring solutions that enable clinicians to make more informed decisions, enhance patient care, and optimize workflows. By combining advanced sensor and signal processing technologies, Masimo Corp strives to address the evolving needs of the medical community. The company's focus on research and development, as well as collaboration with healthcare professionals, reinforces its commitment to pioneering advancements in medical monitoring to benefit patients worldwide.
Analisten hanteren momenteel een gemiddeld koersdoel van 180,21 USD voor het aandeel Masimo (mediaan: 183,60 USD), oftewel +0,1 % ten opzichte van de laatste koers. De consensus is gebaseerd op 16 analistenratings.
15 analisten beoordelen het aandeel Masimo momenteel: 7 adviseren kopen, 8 houden en 0 verkopen. Voor 2026 verwachten analisten dat Masimo een omzet van 1,63 Miljard USD en winst per aandeel van 5,97 USD behaalt.
Omgezet tegen de huidige wisselkoers noteert het aandeel Masimo op 161,16 EUR (179,95 USD).
Het aandeel Masimo (MASI) is genoteerd aan 8 beurzen, waaronder: NYSE (MASI), London (0JZ2.L), SIX (Zürich) (3M4.SW), Frankfurt (3M4.F), München (3M4.MU), Düsseldorf (3M4.DU).
Masimo Corporation is a leading provider of medical diagnostic and monitoring technologies that aim to make patient care safer and more effective. The company is headquartered in California and operates offices worldwide. Masimo's business model can be roughly divided into three areas: 1. Products and technologies Masimo offers a wide range of medical devices and technologies, including pulse oximeters for monitoring oxygen saturation in the blood, capnographs for monitoring end-tidal carbon dioxide concentration, as well as patient monitors and control systems. A highlight is Masimo's Signal Extraction Technology (SET), which is used in almost all of the company's products. SET uses a special algorithm to filter signals from skin color, movement, and other external sources of interference, allowing for accurate measurements. Additionally, Masimo has developed other innovative technologies, such as automatic measurement of hemoglobin levels, which can lead to improved patient outcomes. 2. Services Masimo also offers various services, such as installation, training, and technical support for its products. Furthermore, the company has entered into partnerships with other companies such as Apple and Philips to jointly develop innovative solutions for patient monitoring. 3. Research and development Masimo invests heavily in the research and development of new products and technologies. The company has filed numerous patents and successfully implemented them. By collaborating with clinics and universities, Masimo ensures that its products have informative features and high quality that meet the needs of patients and medical professionals. Overall, Masimo's business model is designed to make healthcare safer and more effective by developing innovative products and technologies, and by providing services and support to its customers. The wide range of products and technologies, as well as the investments in research and development, indicate that Masimo will continue to play an important role in the medical industry in the future.
De verwachte omzet van Masimo bedraagt 1,63 Miljard USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De verwachte winst van Masimo bedraagt 323,74 Miljoen USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van Masimo bedraagt momenteel 30,13. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Masimo-aandeel in te schatten.
De koers-omzetverhouding (P/S) van Masimo bedraagt momenteel 5,97. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Masimo-aandeel.
De Eulerpool Kwaliteitsscore voor Masimo is 5/10.
De ISIN van Masimo is US5747951003. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van Masimo is 578074. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van Masimo is MASI. Onder dit beurstickersymbool wordt het Masimo-aandeel op de beurs verhandeld.
Masimo aandeel
Masimo Peer Group
Masimo Ticker
Masimo FIGI
Alle fundamentals en diepgaande analyse van Masimo
Onze aandelenanalyse van het Masimo-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van Masimo. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: